OR WAIT null SECS
January 25, 2023
The Inflation Reduction Act’s cap on annual out-of-pocket spending and changes to coverage gaps could save Medicare patients more than $1,000 on heart failure medications.
December 10, 2022
A phase 3 study demonstrated that Onpattro improved functional capacity, health status and quality of life compared with placebo in this patient population.
November 30, 2022
If approved, Evkeeza would be the first treatment to help children as young as 5 years old control high LDL cholesterol caused by homozygous familial hypercholesterolemia. The FDA target action date is March 30, 2023.
November 17, 2022
If approved, Xphozah will be the first phosphate absorption inhibitor for adults with chronic kidney disease who are on dialysis. An FDA decision is expected within 30 days.
October 10, 2022
Furoscix can be administered at home with the use of the On-Body Infusor, which delivers furosemide over five hours. It will be launched in the first quarter of 2023.
August 04, 2022
Results indicated the trial is unlikely to meet its primary endpoint, the change from baseline in the six-minute walk test at 24 weeks.
July 15, 2022
A novel therapy in early development aims to permanently turn off the PCSK9 gene in the liver and lower cholesterol with a one-time treatment. It is being developed for a genetic form of high cholesterol.
April 29, 2022
Now called Camzyos, the therapy is first-in-class and treats the underlying cause of the disease. It is expected to be available next week.
March 22, 2022
The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.
March 21, 2022
But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.